Truist analyst Joon Lee says that while Alkermes (ALKS) announced the dual endpoints were met in the Vibrance-2 dose-ranging Phase 2 study evaluating alixorexton in patients with narcolepsy type 2, the “details are scant.” Truist is “comforted” that 95% of patients chose to enter the optional five-week open-label extension, which it believes speaks to a good benefit/risk ratio. The firm has a Buy rating on Alkermes with a $50 price target The stock in morning trading is down 12%, or $3.94, to $29.88.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALKS:
- Alkermes Announces Positive Results from Vibrance-2 Study
- Alkermes down 14% at $29.00 after Vibrance-2 Phase 2 alixorexton study data
- Alkermes’ Alixorexton Shows Promising Results in NT2 Patients, Justifying Buy Rating
- Alkermes says ‘positive’ results from Vibrance-2 Phase 2 study of alixorexton
- DraftKings downgraded, Instacart upgraded: Wall Street’s top analyst calls